NO_LONGER_AVAILABLENot Applicable

Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma

United States

Plain-language summary

Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.

Who can participate

Age range15 Years – 17 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participated in clinical trial * Received pp65 RNA-LPs alone and had pp65/tumor mRNA RNA-LP manufactured * Progressive disease prior to treatment with pp65/tumor mRNA RNA-LP Exclusion Criteria: • Diagnosis of recurrent OSA is not histopathologically confirmed (i.e. pseudoprogression)

Trial details

NCT IDNCT07560709

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Recurrent Osteosarcoma trials